Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biogen Idec Inc. (BIIB),, inc. (CRM): Today’s 3 Worst Stocks

If you somehow glossed over the title of this article, then skipped this paragraph and simply read about the following three stocks without any context, you might think that today was an absolutely miserable day in the markets. It wasn’t, of course: The S&P 500 Index actually picked up momentum in the afternoon and closed 10 points, or 0.6%, higher, at 1,640. Since you’re reading the first paragraph, you deserve to know that Wall Street’s jubilance was due to a feeling that the Fed won’t dare to taper quantitative easing efforts by its next meeting later this month.

Nowhere were shareholders in F5 Networks, Inc. (NASDAQ:FFIV) jubilant today, as they witnessed shares slump 4.9%. After the price target for the stock was lowered at least 10 different times by various investment banks in April, Morgan Stanley (NYSE:MS) downgraded shares today, too, ensuring the networking devices company an awful start to the month of June.

Biogen Idec Inc (NASDAQ:BIIB)

On a similarly unimpressive note, Biogen Idec Inc. (NASDAQ:BIIB) logged its fourth straight day of losses, falling 4.3% by day’s end. No ominous analyst downgrades sullied the stock — in fact it was glowingly positive reviews from analysts about another pharmaceutical company that may have put pressure on shares. Receptos Inc (NASDAQ:RCPT), which is testing a treatment for multiple sclerosis and inflammatory bowel disease, shot up more than 15% after two separate analysts touted the potential for the MS drug. Biogen Idec Inc. (NASDAQ:BIIB), for its part, happens to already make a MS drug that’s been very successful thus far.

Lastly, online sales management platform, inc. (NYSE:CRM) dropped 3.1% Monday. While there was little breaking news today that would seem to justify such a sudden drop, the decline looks less crazy when you consider the fact that the market thinks the company — which didn’t even turn a profit in the last fiscal year — is worth nearly $25 billion. Maybe the valuation is a little ambitious right now for, inc. (NYSE:CRM), a company that can’t translate $3 billion in revenue to a single penny of profit on the bottom line.

The article Today’s 3 Worst Stocks originally appeared on is written by John Divine.

Fool contributor John Divine has no position in any stocks mentioned. You can follow him on Twitter @divinebizkid and on Motley Fool CAPS @TMFDivine.The Motley Fool recommends It recommends and owns shares of F5 Networks.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!